A strain of plant cannabis that won’t make you sick but may help you get stoned has been tested in the wild.
The strain, which has already passed the test, is called the “cannabis flower” and is believed to have a mild sedative effect when ingested.
It is an effort by the company, known as Cultivation, to market the plant as a potential medical treatment, but its commercial potential is being hampered by the government’s ban on cannabis.
The plant is also known as the “black flower” because of its intense black-green colour.
Cultivation is also a pioneer in the cannabis industry, making cannabis oil and cannabidiol (CBD) oil, which have proved useful in treating some ailments.
The company, which sells in the US, UK, and Canada, is hoping that the strain will become a marketable product and attract a new generation of users to its strains.CULTIVATION, the name given to the cannabis plant, has been used for decades to describe the cannabis flower.
It has long been used as a medicine for epilepsy, but now it is widely used to treat other conditions.
The black flower is made by mixing the resin of the cannabis with a plant called a “canna” that is also called a resinifer.
It contains more than 40 cannabinoids and the plants are harvested after harvesting to ensure that the resin is not extracted, so that the plant is a product that can be sold as medicine.
In recent years, the medical cannabis industry has seen a dramatic shift in focus away from producing and selling cannabis, to focusing on growing it.
Its popularity has been largely driven by the use of the plant in a number of industries, including as a food additive, as a medicinal herb, and in pain relief.
It now accounts for nearly 20 per cent of the market in Canada, the US and Australia, according to a report published in the Journal of the American Medical Association in 2016.
Its cultivation has been highly regulated since its inception.
The Federal government, which owns Cultivation shares, has given the company a licence to grow cannabis under its medical cannabis program.
But the company has said it has not obtained any approval from the Department of Health for cultivation, and has not received any federal approval for any commercial cultivation of cannabis.
Its licence has expired, and the company does not intend to renew it.
The CBD oil that Cultivation has been developing is the product that the company hopes will help attract new users to the plant.
The new strain of the flower, known by its trademark name “cabernet sauvignon”, has a lower THC content than its parent, called “cavendish sauvIGNON”.
It is the first strain of Cannabis to pass the tests, which measure the amount of THC in the plant, said the company in a statement.
Its potency is thought to be higher than the “potent” strains in the CBD and THC groups, and that could result in users being able to take a higher dose of the herb.
“The cannabis flower will help us provide consumers with a reliable, affordable and easy-to-use alternative to pharmaceutical products and to alleviate chronic pain,” said Cultivation’s CEO and founder, James Hall.
“It has already been tested and shows promise in treating epilepsy, nausea, and pain, so we are excited to see what the future holds for the cannabis strain.”
The strain is being developed in collaboration with the Netherlands-based company, called Eigen Pharmaceuticals, and is expected to be ready in the third quarter of 2020.
A spokesperson for the company said it was in discussions with the Australian Government about licensing Cultivation to grow CBD in Australia.
“Cultivating is an innovative industry with a long history of innovating, building, and testing new strains of cannabis,” the spokesperson said.
“Our first CBD-based product is based on an original strain developed by Eigen and is the perfect match for CBD-rich food and drink products.”
The spokesperson did not have details on how much Cultivation is making from the CBD oil, but said it had “substantial commitments to develop CBD products in Australia”.